LONZA GROUP AG-REG (LO3.DE) Stock Price & Overview
FRA:LO3 • CH0013841017
The current stock price of LO3.DE is 592 EUR. Today LO3.DE is down by -1.23%. In the past month the price increased by 6.82%.
LO3.DE Key Statistics
- Market Cap
- 41.576B
- P/E
- 27.69
- Fwd P/E
- 27.37
- EPS (TTM)
- 21.38
- Dividend Yield
- 0.94%
LO3.DE Stock Performance
LO3.DE Stock Chart
LO3.DE Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to LO3.DE.
LO3.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to LO3.DE. While LO3.DE is still in line with the averages on profitability rating, there are concerns on its financial health.
LO3.DE Earnings
LO3.DE Forecast & Estimates
30 analysts have analysed LO3.DE and the average price target is 743.91 EUR. This implies a price increase of 25.66% is expected in the next year compared to the current price of 592.
For the next year, analysts expect an EPS growth of 17.79% and a revenue growth 9.56% for LO3.DE
LO3.DE Groups
Sector & Classification
LO3.DE Financial Highlights
Over the last trailing twelve months LO3.DE reported a non-GAAP Earnings per Share(EPS) of 21.38. The EPS increased by 119.51% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 10.33% | ||
| ROA | 3.9% | ||
| ROE | 8.5% | ||
| Debt/Equity | 0.49 |
LO3.DE Ownership
LO3.DE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 56S1 | SARTORIUS STEDIM BIOTECH | 31.68 | 16.994B | ||
| SRT3 | SARTORIUS AG-VORZUG | 35.9 | 16.871B | ||
| DIM | SARTORIUS STEDIM BIOTECH | 30.84 | 16.561B | ||
| SRT | SARTORIUS AG | 29.12 | 13.463B | ||
| QIA | QIAGEN N.V. | 16.86 | 8.353B | ||
| 1SXP | SCHOTT PHARMA AG& CO KGAA | 12.33 | 2.139B | ||
| EVT | EVOTEC SE | N/A | 1.94B | ||
| GXI | GERRESHEIMER AG | 6.33 | 625.865M | ||
| FF | FINE FOODS & PHARMACEUTICALS | 16.27 | 247.072M | ||
| ALECR | EUROFINS CEREP-REGR | N/A | 180M | ||
| MLC | MALIN CORP PLC | N/A |
Related stock screener links
View all stocks in the Life Sciences Tools & Services Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find more growth stocks the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About LO3.DE
Company Profile
Lonza Group AG engages in the supply of pharmaceutical, healthcare, and life science products. The company is headquartered in Basel, Basel-Stadt and currently employs 19,299 full-time employees. The company went IPO on 2002-04-03. The firm's offerings include custom development and manufacturing of drugs and drug delivery systems, as well as development of anti-microbial solutions for commercial applications. The firm divides its activities into two segments: Pharma&Biotech and Specialty Ingredients. The Pharma&Biotech comprises the Company's Biologics, Small-Molecule, and Consumables and Research Tools businesses. The segment includes mammalian, microbial, chemical, bioconjugates, cell and gene therapy technology platforms. The Specialty Ingredients segment focuses on anti-microbial applications within Consumer Health division, which covers hygiene, nutrition and personal care products, as well as preservatives, capsules and food supplements, among others, and Consumer & Resources Protection division, which includes coatings and composites, and agro ingredients.
Company Info
LONZA GROUP AG-REG
Muenchensteinerstrasse 38
Basel BASEL-STADT CH
Employees: 19299
Phone: 41613168111
LONZA GROUP AG-REG / LO3.DE FAQ
What does LO3 do?
Lonza Group AG engages in the supply of pharmaceutical, healthcare, and life science products. The company is headquartered in Basel, Basel-Stadt and currently employs 19,299 full-time employees. The company went IPO on 2002-04-03. The firm's offerings include custom development and manufacturing of drugs and drug delivery systems, as well as development of anti-microbial solutions for commercial applications. The firm divides its activities into two segments: Pharma&Biotech and Specialty Ingredients. The Pharma&Biotech comprises the Company's Biologics, Small-Molecule, and Consumables and Research Tools businesses. The segment includes mammalian, microbial, chemical, bioconjugates, cell and gene therapy technology platforms. The Specialty Ingredients segment focuses on anti-microbial applications within Consumer Health division, which covers hygiene, nutrition and personal care products, as well as preservatives, capsules and food supplements, among others, and Consumer & Resources Protection division, which includes coatings and composites, and agro ingredients.
What is the current price of LO3 stock?
The current stock price of LO3.DE is 592 EUR. The price decreased by -1.23% in the last trading session.
What is the dividend status of LONZA GROUP AG-REG?
LONZA GROUP AG-REG (LO3.DE) has a dividend yield of 0.94%. The yearly dividend amount is currently 4.36.
What is the ChartMill technical and fundamental rating of LO3 stock?
LO3.DE has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Is LONZA GROUP AG-REG (LO3.DE) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on LO3.DE.
What is the next earnings date for LO3 stock?
LONZA GROUP AG-REG (LO3.DE) will report earnings on 2026-07-21.